Mon panier

Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag™ (Nanodisc-pro)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-H82D3-20ug
$1020.00
CD0-H82D3-100ug
$1820.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Nanodisc-pro Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (CD0-H82D3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a Flag tag at the N-terminus and a polyhistidine tag at the C-terminus followed by an Avi tag (Avitag™). The protein has a calculated MW of 39.1 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H8113) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc-pro membrane protein is wrapped by a piece of cell membrane and scaffold, the info of scaffold can be found in above red text "isotope type control...".

    2. Synthesis Process

      Nanodisc-pro membrane protein extraction is a gentle, non-disruptive process that directly isolates full-length transmembrane proteins together with their surrounding native phospholipids from cellular membranes, without breaking or disturbing the original membrane structure. This preserves the membrane protein's natural conformational landscape and native lipid environment, yielding stable nanodisc that retain cellular phospholipids, with fully preserved biological activity—making them ideal for cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA), etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.6-39 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Ofatumumab biosimilar with a linear range of 0.001-0.078 μg/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Obinutuzumab biosimilar with a linear range of 0.03-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     CD20 SPR

    Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) immobilized on SA Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 240 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     CD20 FACS

    2e5 of Anti-CD20 CAR-293 cells were stained with 100 μL of 3 μg/mL Biotinylated Human CD20 Full Length Protein, FlagTag&His,Avitag (Cat. No. CD0-H82D3) and negative control protein respectively, washed and then followed by PE-SA and analyzedwith FACS (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD20

  • Catégorie:

  • Nombre de médicaments répertoriés:

    35 Détails

  • Nombre de médicaments cliniques:

    132 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte